New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone ... - Gamut News (press release) PDF Print
Gamut News (press release)
In the US there are more than 26 million patients with CKD, and more than 450000 patients with end-stage renal disease (ESRD). Bardoxolone methyl is a novel, first-in-class antioxidant inflammation modulator (AIM). Bardoxolone activates the Nrf2

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.

Notice: Undefined variable: query in /home/globaldi/public_html/components/com_joomlawatch/class.joomlawatch.db.php on line 129